

Prognosis of Urinary Bladder TCC in Young Adults: A Single Center Experience

Rajeev T.P

Received: 11 December 2017 Accepted: 2 January 2018 Published: 15 January 2018

Abstract

Introduction: Bladder TCC is rare in young adults and occurs more commonly in elderly individuals. The incidence of TCC urinary bladder is found to be 1

Index terms— TCC urinary bladder, recurrence, progression, grade, multifocality, smoking, recurrence-free survival, progression-free survival.

1 I. Introduction

Transitional cell carcinoma (TCC) urinary bladder is the fourth most common neoplasm in men and eighth most common neoplasm in women in the Western world. Urinary bladder cancer is rare in young Adults and occurs more commonly in elderly individuals. The median age of presentation for men is usually 69 yrs and for the female is 71 yrs respectively [1,2]. TCC urinary bladder incidence below the age of 40 years is 1% -2.4% only. Younger population has incidence of only .1% -.4% (age less than 20 yrs) [3,4]. Although the genomic nature and management of bladder cancer have been well researched, inconclusive reports exist about clinical pattern and prognosis for patients less than 40 years of age. Whether younger cases have a superior prognosis than their aged counterparts has long been a subject of contention; indeed, some reports projected similar patterns of clinical behavior and prognosis for TCC bladder in young and older patients, whereas other reports displayed lower rates of disease recurrence and progression, and superior outcome survival, in younger patients [5][6][7][8].

Among the probable risk scenarios expected in TCC bladder, tobacco consumption is most crucial and is responsible for 48% cases in males and 32% in females in the developed world [9]. Environmental factors in the form of occupational exposure, chemical and treatment exposure along with family history plays an important role in the etiopathogenesis of TCC bladder. In our analysis though majority of our patients were young tobacco consumers, we still noticed that a sizeable chunk did not have significant smoking exposure. The acute rise in these cases (NE India) in the past 2 decades bears testimony to the everincreasing health hazards being faced by the population in this part of the world comprising of multiethnic population. An Indian study published data on patients diagnosed with TCC Urinary bladder and reported median age between 65-70 years. Moreover, there was a male preponderance (86.4% male vs. 13.6% female). Tobacco smoking (75% cases) revealed a strong relationship with TCC bladder which was quantity and duration dependent [9]. Another Indian study reported data collected from the Bombay Cancer Registry and found that bladder cancer was very uncommon in the first three decades of life [10]. Nonetheless, past 30 years of age, the incidence rates increase with age, in log-linear fashion, in both genders. The Indian T subcontinent data differ from the Western counterpart in two aspects. First, the contrast in the incidence of smoking among Indian men and women is much more distinguished (74% vs. 22%) than in the West. Second, the incidence of TCC bladder per se is much more cardinal in Indian men (8.9:1). The vast majority of bladder cancer in men versus women is explained by the smoking habits of men and estrogen-progesterone hormonal influence in the female reproductive life [11][12][13][14].

Most urinary bladder cancers consist of TCC, which can be classified into different categories with unique clinical pattern [15]. Low-grade, papillary lesions usually do not involve the muscle but often recur locally, demanding long-term surveillance. In contrast, high grade, non-papillary lesions are more prone for deeper invasion into the muscle layer and to metastasize, resulting in significant mortality. Contemporary studies have projected that papillary and non-papillary lesions may use various diabolical biological pathways, which may lead to their distinct biological manifestations [16]. Past analysis of patients with TCC bladder has used different denotation of young age, ranging from 20 years to 40 years. This diversion has led to inconsistent outcomes

3 III. RESULTS

47 regarding the clinic-pathologic features of this dreaded disease in young individuals. Additionally, because TCC
48 bladder is rare in young patients, most studies in these patients have been small series with the number of
49 reported cases ranging from 12 to 50 [17]. To better characterize the clinic-pathologic features of TCC urinary
50 bladder in young patients, we retrospectively evaluated a series of 71 cases in which clinical behavior, pathological
51 outcomes, and disease recurrence and survival characteristics in patients with bladder TCC that were younger
52 than 40 years of age. We compared our data with a matched cohort of young (Group A: \leq 30 years Vs, Group B:
53 31-40 years) patients with bladder TCC and intended to discover the difference in behavior of the disease between
54 the two cohorts. The authors got on board to navigate the unexplored domain of TCC bladder with an aim to
55 ascertain causality & risk factors predisposing to an early event, evaluate factors affecting disease recurrence and
56 progression, estimation of survival characteristics and exact follow-up and radiological imaging schedule.

2 II. Methods

58 After obtaining institutional ethics committee clearance, a retrospective review of our records between Jan 2006
59 and Dec 2012 identified 71 patients (43 males and 28 females) with transitional cell carcinoma of the bladder
60 who were less than 40 years old. Clinical and pathological parameters of patients who were \leq 30 years of age
61 were compared with those of patients between 31-40 years of age during the same period. Epidemiological and
62 demographic data, including patient's age at presentation, gender, time of starting and total duration of smoking,
63 presenting clinical symptoms, initial HPE report, tumor size and locations, stages and grades at initial TURBT,
64 recurrence events and disease progression to different grades or stages, and metastatic status, were collected. The
65 2004 WHO International Society of Urologic Pathology and 2002 tumor stage classification were used to evaluate
66 the stages and grades of TCC bladder. Patients with nontransitional cell variety and upper tract TCC were
67 excluded from the analysis. Disease recurrence was defined as the return of the disease at any site within bladder
68 and progression was defined as upstage in tumor stage/grade. Moreover, recurrence or progression-free periods
69 were defined as the dates of initial diagnosis of bladder cancer and those of disease recurrence or progression.
70 Patients less than 40 years old were divided into two subgroups according to the age of presentation: younger than
71 30 years old and between 31 and 40 years old. Data among the groups were analyzed using the Chi-square test
72 and Pearson's R test. Recurrence-free survival (RFS) & progressionfree survival (PFS) analyses were performed
73 using the Kaplan Meier method and log-rank test. Multivariate cox proportional hazards analysis, was outlined
74 to identify independent predictors of the recurrence of TCC of the bladder in patients less than 40 years old.
75 All statistical analyses were performed using SPSS version 21. A p value of <0.05 was considered statistically
76 significant.

3 III. Results

78 We analyzed all relevant data between Jan' 2006 and Dec' 2012 and 71 patients (43 men and 28 women) with
79 TCC of the bladder who were \leq 40 years old were included in the study with subgroup analysis of \leq 30 years
80 ($n=30$) and 31 -40 years ($n=41$). For the two retrospective cohorts, the mean age at diagnosis was 24.21 years
81 (range, 20.25-28.57 years) and 37.66 years (range, 34.50-39.67) with an overall male to female ratio of 1.54:1.
82 The mean \pm SD (overall) follow up time was 47.41 months (range, 12-65 months) (Table 2). Male and female
83 distribution in the 2 groups is shown in Figure 1.

84 The mean (\pm SD) pack year for tobacco smoking in the age group \leq 30 yrs was 30.22 ± 4.36 ($p=.418$) while
85 that for age group \leq 30 yrs was 10.25 ± 2.14 years. Similarly, mean \pm SD pack year for tobacco smoking in the
86 age group 31-40 yrs was 44.63 ± 6.18 while mean \pm SD smoking duration for age group \leq 30 yrs was 18.75 ± 5.14
87 yrs. The total number of active smokers in the group 1 was 53.3% while in the group 2 was 75.6% (Chi-square
88 coefficient = 3.84, $p= .048$) (Table 1). Smoking was defined in the current study as > 100 cigarettes consumption
89 overall as per the NIHS definition and was found to be significantly associated and correlated with TCC urinary
90 bladder in the study (Pearson's R = .233, $p = .047$). Presence of risk factors was also ascertained and among all
91 the risk factors mentioned above, the presence of any one risk factor was considered positive, though not found to
92 be significantly associated or correlated. There were 13.3% patients in the Group A (smoking + RF group), and
93 36.6% patients in the group B and both the groups were significantly associated and correlated with the same.

94 Macroscopic hematuria was the presenting symptom in 43.3% in the group A and in 58.5 % in the group B.
95 Similarly, microscopic hematuria was the presenting symptom in 33.3% in the group A and 22 % in the group
96 B. UTI / irritative voiding was the presenting symptom in 23.3% in the group A and 19.5 % in the group B
97 (Figure 2). The mean time from the onset of symptoms to diagnosis was 38 days (range 14 -67). Family history
98 of TCC UB was present in 13 The clinical scenario of study population is presented in (Table 3). The most
99 common T stage in the group A was Ta (70%) followed by T1 (23.3%) while in the group B, the incidence of
100 both the groups was similar (23.3%). The distribution of the T stage in both the groups was not significantly
101 associated or correlated (Table 2). Tumor grading (2004, ISUP) was distributed as low grade in 56.7% followed
102 by high in 26.7% in the group A. In the group B however, the maximum number of cases were PUNLMP (43.9%)
103 followed by a low grade as a distant second (31.7%). All these grade distributions were found to be significantly
104 associated and correlated in the two groups (Table 4)]. Incidence of the high grade was almost similar in both
105 the groups at 26.7% and 24.4% respectively, but it was found that the younger cohort had more high -grade
106 and lowgrade TCC's combined (Table 2) as compared to 31-40 years age group. Aforementioned result comes

107 as a stark contrast to the belief that early age group behaves less aggressively than their aged counterparts as
108 described in literature. Multifocal tumors were found to be present in 78% of the group B vis a vis 36.7% in
109 the group A (significantly associated & correlated) (Table 4). Tumor size \geq 2.5 cm was seen in 20% cases in the
110 group A and 14.6% cases in the group B. Tumor size was not found to be significantly associated or correlated
111 within the two respective groups (Table 4).

112 Tumor recurrence was seen in 16.7% cases in the group A and 43.9% in the group B and was significantly
113 associated (Chi square coefficient =4.42, $p=.045$) and correlated (Pearson's R =.250, $p=.036$) (Table 5). One out
114 of the total five recurrences (Ta, HG) in group A occurred within 3 months while the other 4 recurrence (Ta +
115 T1, HG) occurred at 12 months. Nine out of the 18 recurrence in the group B (Ta + T1, HG) occurred within 3
116 months while 6/18 recurrence (Ta + T1, HG) occurred at 6 months. Three cases recurred between 18-24 months
117 (Group B).

118 Tumor progression was seen in 6.7% cases in the group A and 36.6% in the group B and was significantly
119 associated (Chi-square coefficient =7.12, $p=.011$) and correlated (Pearson's R =.346, $p=.003$). Among grade
120 progression in the group A, one stage migration was observed from Ta to T1, and 1 from T1 to T2 and both
121 occurred at 12 months of follow up. In the group B, 7 progressions from low grade to high grade TCC occurred
122 at three months of follow up and five progressions from PUNLMP to Low grade at six months. Three cases
123 progressed from low grade to high grade in between 18-24 months.

124 Multivariate logistic regression analysis projected tumor recurrence in study population with high-grade tumors
125 [odds ratio (OR), 1.895; 95% confidence interval (CI),-.901-2.125; $p = 0.036$] and multifocality (OR, 2.310; 95%
126 CI, .941-3.341; $p < 0.005$) (Table 6).The Kaplan Meier method was used to estimate the (RFS) recurrence free
127 survival and (PFS) progression free survival. The 5-year RFS was 83% for group A and 56.1% for group B and
128 the difference was found to be significant ($p= .018$) between the 2 groups. The 5-year PFS was 93.2 % for group
129 A and 63.4 % for group B and the difference was found to be significant ($p= .005$) between the 2 groups.

130 4 IV. Discussion

131 TCC urinary bladder in younger population (\geq 40 years) is a rare entity, with an incidence rate of only 0.8%
132 [18]. There is a paucity of evidence regarding validated literature when comparing clinical pattern and outcomes
133 of bladder TCC in younger patients especially \geq 30 years and 31-40 years. To our knowledge there are hardly
134 any studies except one or two regarding the subgroup analysis in population concerning TCC urinary bladder.
135 As per the available studies the low-Ta tumor recurs at a rate of 50% to 70% and progress in 5% of cases while
136 the high-grade T1 tumor recur in more than 80% of cases and progress in 50% of patients within 3 years. Our
137 analysis in part confirm the reverberation of previous reports and projects that patients \geq 30 years of age had
138 less recurrence (20% as compared 44%, $p < .05$) and progression (6.7% as compared to 36.6%, $p < .05$) than
139 their counterparts in group B. This finding is supported by previous study results [19]. Notwithstanding the
140 aforementioned fact, Group A did have high number of high grade TCC as compared to the group B. In our
141 analysis, younger patients had more high-grade cancers than their aged counterparts (26.7% vs. 24.4%, $p < .05$)
142 and more tumors $>$ 2.5 cm in size (20% vs. 14.6%), which was similar to the findings of previous retrospective
143 studies [20]. Nonetheless, in the Surveillance, Epidemiology and End Results (SEER) database (1973 to 2003),
144 of 140 bladder tumors affecting patients younger than 18 years old, 50.7% were diagnosed as PUNLMP. Thus,
145 PUNLMP is regarded as the most common grade within this age group [21]. According to a recent analysis,
146 although there is a preponderance of low-grade TCC in the first three decades of life, the grade distribution of
147 TCC urinary bladder in older patients is not exactly comparable to those in the fourth decade of life which is also
148 validated from our study results [22]. In our study, a male dominance was observed (male: female ratio 1.54:1)
149 but which was below to those reported in previous analysis [23][24][25]. In both the groups under evaluation,
150 the major presenting symptom was macroscopic hematuria with no significant difference between the younger
151 and older patients. In a recent review of children with gross hematuria, causes of which consisted of infection,
152 stones and malignancy, only three cases were diagnosed to have TCC bladder [26]. We have displayed in our
153 analysis that stage distribution of patients aged 31-40 years with bladder TCC was not significantly different
154 from their older counterparts, which is in concordance with some past published studies. In contrast, younger
155 patients had slightly higher invasive disease which some studies indicated were due to CK20 along with mismatch
156 repair proteins (MRPs) hMSH2, hMLH1, and hMSH6 along with FGFR3 [27]. We have analyzed our present
157 data with the past studies and have found a comparable result thus validating our results (Table 7).

158 The Mantle Cox Log Rank was applied to estimate the five year RFS and five year PFS. The 5 yr RFS for
159 the Group A was 83%, (Figure ??) while it was only 56.1 % for the Group B (Chi square 5.608, $p =.018$). The
160 mean recurrence free survival was an estimated 55.84 months (95% C.I. -49.32-62.36) for the group A while it
161 was 43.40 months (95% C.I: 35.91-50.89). The 5 yr PFS for the Group A was 93.2 %, (Figure ??) while it was
162 63.4 % grade.

163 For the Group B (Chi square 7.93, $p =.005$). The mean progression free survival was an estimated 61.84
164 months (95% C.I: 57.90 -66.02) for the group A while it was 48.74 months (95% C.I: 42.18 -55.30). To our
165 misfortune, we could not do an extensive analysis because of the small number of cases, lack of sound and apt
166 information, and short follow-up period. Our study was limited by the fact that it was a retrospective study
167 with inherent disadvantages, lack of CIS information in biopsy, lack of urine cytology information, correct age

5 V. CONCLUSION

168 at start of smoking and exact duration of smoking before first symptom appearance and patient belonging to
169 multiethnic groups.

170 5 V. Conclusion

171 TCC urinary bladder is a heterogeneous disease with high prevalence and recurrence rates. The present analysis
172 provides useful reckoning of survival outcome, with aggressive treatments reserved for patients with higher stage
173 disease. The analysis projected similar low grade TCC in both the groups but slightly higher high grade lesions
174 in the younger Group A, though the exact reason is still under consideration. Multifocality and tumor grade
175 were the predominant factors associated with early recurrence and progression. We found out that smoking
176 alone and along with other risk factors (as confounding factor) contribute significantly to the recurrence and
177 progression risk profile. We also concluded that a strict follow up at 3 month and till 12 months for low grade
178 + PUNLMP is a bare minimum while it's strictly every 3 month for first 2 yrs for high grade lesion. Although
179 this ontological event is less frequent in young adults, its effects remain substantial because these cases have a
180 large chunk of their life still undiscovered and many responsibilities to fulfill. Since young age carcinoma exhibit
181 a combination of features seen in younger and older patients, treatment protocol needs to evolve in such a way so
182 as to provide prompt diagnosis and most suitable treatment scheme. Future endeavors focus on advancement of
183 risk stratification and treatment protocols through clinical trials in young cases and implementation of effective
prevention and early detection at middle ages. Grants: None





Figure 1: Figure 1 :

184



2

Figure 2: Figure 2 :

Figure 3:

1

Variable	? 30 yrs n, (%)	31 -40 yrs n, (%)	Total	Chi Square Coefficient	p Value
Patients	30 (42.3)	41 (57.7)	71		
Mean Age (range)			33.45(22-40)		
Sex (M/F)	18/12	25/16	43/28	.007	.934
Mean Follow Up (SD)	45.67± 11.40	49.15± 12.13	47.41 ± 12.74	.114	.430
Smoking (NHIS , > 100 cigarettes)	16 (53.3)	31 (75.6)	47 (66.2)	3.84	.048
Risk Factor*	10 (33.31)	19(46.3)	29(40.8)	1.213	.271
Smoking + Risk Factor	4 (13.3%)	15(36.6)	19(26.8)	4.77	.029

Figure 4: Table 1 :

2

Variable	Pearson R correlation Coefficient	p Value
Sex (M/F)	.010	.935
Mean Follow Up (SD)	.005	.847
Smoking (NHIS , > 100 cigarettes)	.233	.047
Risk Factor*	.131	.371
Smoking + Risk Factor	.259	.029

Figure 5: Table 2 :

3

Variable	? 30 yrs n =30(42.3%)	31 -40 yrs n =41(57.7%)	Total	Chi Square Coefficient	p Value
Clinical Presentation				1.72	.422
Microscopic Hematuria	10(33.3)	9(22)	19(26.8)		
Macroscopic Hematuria	13(43.3)	24(58.5)	37(52.1)		
Irritative voiding / UTI	7(23.3)	8(19.5)	15(21.1)		
T Stage				14.75	.060
Ta	21(70)	12(29.3)	33(46.5)		
T1	7(23.3)	12(29.3)	19(26.8)		
T2	2(6.7)	10(24.4)	12(16.9)		
T3	0	4 (9.8)	4 (5.6)		
Grade				16.56	.039
PUNLMP	5(16.7)	18(43.9)	23(32.4)		
Low Grade	17(56.7)	13 (31.7)	30 (42.3)		
High Grade	8(26.7)	10(24.4)	18(25.4)		
Multifocal					
>1 lesion	11(36.7)	32(78)	43(60.6)	12.42	.001
Tumor Size (? 2.5 cm)	6(20)	6(14.6)	12(16.9)	.355	.550

Figure 6: Table 3 :

4

Variable	Pearson R correlation Coefficient	p Value
Clinical Presentation		
Microscopic Hematuria Macroscopic Hematuria	.054	.654
Irritative voiding / UTI		
T Stage	.873	.114
Grade	4.52	.001
Multifocal >1 lesion	.488	.001
Tumor Size (? 2.5 cm)	.071	.350

Figure 7: Table 4 :

5

Variable	? 30 yrs n =30(42.3%)	31 -40 yrs n =41(57.7%)	Total	Chi Square Coefficient	p Value
Tumor recurrence	5(16.7)	18 (43.9)	24 (33.8)	4.42	.045
Tumor Progression	2(6.7)	15 (36.6)	17(23.94)	7.12	.011

Figure 8: Table 5 :

6

Variable	Odds ratio	95% C.I.	p Value
Sex			
(Male)	.984	.672 -1.441	
(Female)	1.025	.573 -1.815	.071
Grade			
PUNLMP	1.000	.901 -2.125	.036
Low Grade	1.013		
High Grade	1.895		
T Stage			
Ta/T1	1.011	.810 -1.954	.065
T2/T3	1.781		
Multifocality			
? 1 lesion	1.000	.941-3.341	.005
>1 lesion	2.310		
Tumor Size			
?2.5 cm	.918	.814-1.245	.544
>2.5 cm	1.101		

Figure 9: Table 6 :

7

Author	Number of cases	Mean follow up (months)	Superficial Bladder Cancer (%)	Invasive Bladder Cancer (%)	Recurrence (%)	Progression (%)
Wen et al. 12	30	72.8	76	23.4	50	8.3
Yossepowitch et al. 14	74	28.1	83	16.6	38.7	16
Erozenci et al. 28	156	87	89.1	10.9	48.7	22.8
Perez et al. 29	30	66	67.6	23.3	32	0.1
Present Study	71	45	73.2	33.8	33.8	23.94

Figure 10: Table 7 :

-
- 185 [Biswas et al. ()] 'An Epidemiological Study of Cases of Urothelial Carcinoma of Urinary Bladder in a Tertiary
186 Care Centre'. R R Biswas , S Mangal , D Guha , K Basu , D Karmakar . *JKIMSU* 2013.
- 187 [Wan and Grossman ()] 'Bladder carcinoma in patients aged 40 years or younger'. J Wan , H B Grossman .
188 *Cancer* 1989. 64 p. .
- 189 [Witjes and Debruyne ()] 'Bladder carcinoma in patients less than 40 years of age'. J A Witjes , F M Debruyne
190 . *Urol Int* 1989. 44 p. .
- 191 [Johnson and Hillis ()] 'Carcinoma of the bladder in patients less than 40 years old'. D E Johnson , S Hillis . *J*
192 *Urol* 1978. 120 p. .
- 193 [Yeole and Jussawalla ()] 'Descriptive epidemiological assessment of urinary bladder and kidney cancers in
194 Greater Bombay'. B B Yeole , D J Jussawalla . *Indian J Med Res* 1997. 106 p. .
- 195 [Murta-Nascimento et al. ()] 'Epidemiology of urinary bladder cancer: from tumor development to patient's
196 death'. C Murta-Nascimento , B J Schmitz-Dra"ger , M P Zeegers , G Steineck , M Kogevinas , F X Real .
197 *World J Urol* 2007. 25 p. .
- 198 [Wild et al. ()] 'Genomic aberrations are rare in urothelial neoplasms of patients 19 years or younger'. P J Wild
199 , J Giedl , R Stoehr , K Junker , S Boehm , J M Van Oers , E C Zwarthoff , H Blaszyk , S W Fine , P A
200 Humphrey , L P Dehner , M B Amin , J I Epstein , A Hartmann . doi: 10.1002 / path.207. *J. Pathol* 2007.
201 211 (1) p. .
- 202 [Greenfield et al. ()] 'Gross hematuria in children: a ten-year review'. S P Greenfield , P Williot , D Kaplan .
203 *Urology* 2007. 69 p. .
- 204 [Habuchi et al. ()] 'Hypermethylation at 9q32e33 tumour suppressor region is age-related in normal urothelium
205 and an early and frequent alteration in bladder cancer'. T Habuchi , T Takahashi , H Kakinuma , L Wang ,
206 N Tsuchiya , S Satoh . *Oncogene* 2001. 20 p. .
- 207 [Fedewa et al. ()] 'Incidence analyses of bladder cancer in the Nile delta region of Egypt'. S A Fedewa , A S
208 Soliman , K Ismail , A Hablas , I A Seifeldin , M Ramadan . *Cancer Epidemiol* 2009. 33 p. e81.
- 209 [Bujons et al. ()] 'Long-term follow-up of transitional cell carcinoma of the bladder in childhood'. A Bujons , J
210 Caffaratti , J M Garat , H Villavicencio . *J. Pediatr. Urol* 2014. 10 p. .
- 211 [Neogi et al. ()] 'Malignant urothelial carcinoma of urinary bladder in a young child: a rare case report'. S Neogi
212 , P L Kariholu , G Dhakre , V Gupta , N Agarwal , P Bhadani . *Urology* 2013. 81 p. .
- 213 [Sobin et al. ()] H Sobin , M Gospodariwicz , C Wittekind . *TNM classification of malignant tumors*, 2009.
214 Wiley-Blackwell. (7th ed.)
- 215 [Linn et al. ()] 'The molecular characteristics of bladder cancer in young patients'. J F Linn , I Sesterhenn , F K
216 Mostofi , M Schoenberg . *J Urol* 1998. 159 p. .
- 217 [Kurz et al. ()] 'The natural history of patient less than 40 years old with bladder tumors'. K R Kurz , W R
218 Pitts , Vaughan Jr , ED . *J Urol* 1987. 137 p. .
- 219 [Epstein et al. ()] 'The World Health Organization/International Society of Urological Pathology consensus
220 classification of urothelial (transitional cell) neoplasms of the urinary bladder: Bladder Consensus Conference
221 Committee'. J I Epstein , M B Amin , V R Reuter , F K Mostofi . *Am J Surg Pathol* 1998. 22 p. .
- 222 [Keetch et al. ()] 'Transitional cell carcinoma of the bladder in children and adolescents'. D W Keetch , C B
223 Manley , W J Catalona . *Urology* 1993. 42 p. .
- 224 [Erozenci et al. ()] 'Transitional cell carcinoma of the bladder in patients under 40 years of age'. A Erozenci , S
225 Ataus , A Pekyalcin , A Kural , Z Talat , V Solok . *International Urology and Nephrology* 1994. 26 (2) p. .
- 226 [Ozbey et al. ()] 'Transitional cell carcinoma of the bladder in patients under 40 years of age'. I Ozbey , Y Aksoy
227 , O Bicgi , O Polat , G Okyar . *Int Urol Nephrol* 1999. 31 p. .
- 228 [Kutarski and Padwell ()] 'Transitional cell carcinoma of the bladder in young adults'. P W Kutarski , A Padwell
229 . *Br J Urol* 1993. 72 p. .
- 230 [Yossepowitch and Dalbagni ()] 'Transitional cell carcinoma of the bladder in young adults: presentation, natural
231 history and outcome'. O Yossepowitch , G Dalbagni . *J Urol* 2002. 168 p. .
- 232 [Perez et al. ()] 'Transitional cell carcinoma of the bladder: behavior in young adults'. J Perez , C Smet , R
233 Pareja . *Archivos Espanoles de Urologia* 1996. 49 (6) p. .
- 234 [Compe´rat et al. ()] 'Urothelial carcinoma in patients under 40 years. Review of the cancer committee of the
235 French Association of'. E Compe´rat , P Camparo , S Larre´ , M Roupret , Y Neuzillet , G Pignot . *Urology*
236 *Prog Urol* 2013. 23 p. .
- 237 [Wen et al. ()] 'Urothelial carcinoma of the urinary bladder in young adults: clinical experience at Taipei
238 Veterans General Hospital'. Y C Wen , J Y Kuo , K K Chen , A T Lin , Y H Chang , Y S Hsu . *J*
239 *Chin Med Assoc* 2005. 68 p. .

5 V. CONCLUSION

- 240 [Nomikos et al. ()] ‘Urothelial carcinoma of the urinary bladder in young adults: presentation, clinical behavior
241 and outcome’. M Nomikos , A Pappas , M E Kopaka , S Tzoulakis , I Volonakis , G Stavrakakis . *Adv Urol*
242 2011. 2011. p. 480738.
- 243 [Paner et al. ()] ‘Urothelial neoplasms of the urinary bladder occurring in young adult and pediatric patients: a
244 comprehensive review of literature with implications for patient management’. G P Paner , P Zehnder , A M
245 Amin . *Adv. Anat. Pathol* 2011. 18 p. .
- 246 [Paner et al. ()] ‘Urothelial neoplasms of the urinary bladder occurring in young adult and pediatric patients: a
247 comprehensive review of literature with implications for patient management’. G P Paner , P Zehnder , A M
248 Amin , A N Desai , MM . *Adv Anat Pathol* 2011. 18 p. .
- 249 [Stanton et al. ()] ‘Urothelial tumors of the urinary bladder in young patients: a clinicopathologic study of 59
250 cases’. M L Stanton , L Xiao , B A Czerniak , C C Guo . *Arch. Pathol. Lab. Med* 2013. 137 p. .
- 251 [Eble et al. ()] *World Health Organization classification of tumours. Pathology and genetics. Tumours of the*
252 *urinary system and male genital organs*, J N Eble , G Sauter , J I Esptein . 2004. Albany, NY: Who
253 Publication Center. p. .